Price
No data yet.
Social Signal Score
Analyst Ratings
49 analystsRevenue
$2.80B-2.36%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher A. Viehbacher
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 7,500
- Beta
- 0.17
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 3.15
Financials
Revenue
$2.80B-2.4%Net Income
$-20.60M-103.2%EBITDA
$319.60M-79.9%Free Cash Flow
$600.40M-56.9%EPS (diluted)
$-0.14-104.7%Shares Outstanding (diluted)
147.80M-31.9%Operating Expenses
$1.33BCash & Debt
$1.30BReturn of Capital
$0.00Revenue by Segment (annual)
$9.62BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $9.89B | $1.29B | $8.83 |
| 2024 | $9.68B | $1.63B | $11.20 |
| 2023 | $9.84B | $1.16B | $8.02 |
| 2022 | $10.17B | $3.05B | $20.97 |
| 2021 | $10.98B | $1.56B | $10.44 |
| 2020 | $13.44B | $4.00B | $24.86 |
| 2019 | $14.38B | $5.89B | $31.47 |
| 2018 | $13.45B | $4.43B | $21.62 |
| 2017 | $12.27B | $2.54B | $11.94 |
| 2016 | $11.45B | $3.70B | $16.96 |
| 2015 | $10.76B | $3.55B | $15.38 |
| 2014 | $9.70B | $2.93B | $12.42 |
| 2013 | $6.93B | $1.86B | $7.86 |
| 2012 | $5.51B | $1.38B | $5.80 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BIIB's reported EPS growth of 3.3% a year over 13 years.
- EPS in 5 years
- $10.38
- Implied price
- $207.62
- Return from $247.13
- -3.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $103.22 — -58.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -6.7% | -18.8% | -15.6% | -12.8% | -10.3% | -8.1% |
| -1.7% | -14.4% | -11.0% | -8.1% | -5.5% | -3.1% |
| 3.3% | -10.1% | -6.5% | -3.4% | -0.7% | 1.8% |
| 8.3% | -5.7% | -2.0% | 1.2% | 4.1% | 6.7% |
| 13.3% | -1.4% | 2.5% | 5.9% | 8.9% | 11.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
75+50.00%Social Signal Score
Mentions (46)
- News (RSS)seekingalpha·2d ago·Positive
Biogen: Why I'm Still Bullish Despite Market Turmoil
View source ↗ - News (RSS)seekingalpha·3d ago·Negative
Biogen: M&A Growth And Alzheimer's Progress Are Now Priced In (Rating Downgrade)
View source ↗ - Newsseekingalpha.com·3d ago·Negative
…n (Rating Downgrade) Biogen Inc. moves from Buy to Hold: after a 20% gain, its valuation reasonably reflects growth and marginally positive Alzheimer's developments. BIIB trades above my July $223.70 DCF estimate; raising assumed growth from 2.5% to 3.5% yields $241.38, closer to its current price. Diranersen's two-year data are encouraging, but its Phase 2 trial missed its primary endpoint, and an inverse dose response complicates Phase 3.
View source ↗ - Newsprnewswire.com·4d ago·Neutral
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026 Largest analysis of LEQEMBI LEADER study reported to date includes findings on amyloid clearance in routine clinical practice, delayed progression to moderate or severe AD, expanded subcutaneous maintenance experience, and additional sex-based outcomes TOKYO and CAMBRIDGE, Mass., Nov. 18, 2026 /PRNewswire/ -- Eisai Co., Ltd.
View source ↗ - News (RSS)fool·4d ago·Positive
Biogen: 3 Key Takeaways for Long-Term Investors Late-stage trials could reshape the rare disease franchise, but the real story is whether the pipeline matters at all.
View source ↗ - News (RSS)seekingalpha·5d ago·Positive
Biogen Inc. (BIIB) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Biogen Inc. (BIIB) Presents at Jefferies Global Healthcare Conference 2026 Transcript Biogen Inc. (BIIB) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsprnewswire.com·6d ago·Neutral
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026 Benefits of continuous lecanemab treatment in early Alzheimer's disease accrue over time Lecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI 62% of patients with low tau showed improvement in cognitive function and activities of daily living (CDR-SB) at five years TOKYO and CAMBRIDGE, Mass.
View source ↗ - News (Marketaux)manilatimes.net·13d ago·Positive
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure ., Nov. 09, 2026 (GLOBE NEWSWIRE) -- UCB[+274 characters]
View source ↗ - Newsbenzinga.com·24d ago·Positive
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.
View source ↗ - Newsmarketbeat.com·25d ago·Neutral
Biogen Q3 Earnings Call Highlights Biogen NASDAQ: BIIB reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio. Management said the company remains on track to return to top-line growth in 2026 and raised the lower end of its full-year non-GAAP diluted earnings-per-share guidance.
View source ↗ - Newszacks.com·25d ago·Negative
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
View source ↗ - News (RSS)zerohedge·25d ago·Neutral
…LBI up 144% premarket. CoStar will buy Vexcel for about $730 million in cash. TPG is in talks to buy Ark Data Centres at a $5 billion valuation, according to the FT. Biogen now sees full-year adjusted EPS of $12.20 to $13, compared with $12 to $13 previously.Globally, it is the AI trade that is back in the driver's seat: the tech rally led Asian stocks higher, with South Korea's Kospi jumping nearly 7% following blowout results from SK Hynix, Nasdaq-100 futures outperforming S&P 500 and European…
View source ↗ - Newszacks.com·25d ago·Neutral
Big Day for Econ Data, Hyperscaler Earnings We have a solid slate of reports today, both of the earnings variety and regarding economic growth.
View source ↗ - Newszacks.com·25d ago·Positive
Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates Biogen Inc. (BIIB) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $4.81 per share a year ago.
View source ↗ - Newswsj.com·25d ago·Negative
Biogen Swings to Loss, Logs Higher Sales The biotechnology company said the swing to a loss was primarily due to transaction-related charges.
View source ↗ - Newszacks.com·30d ago·Positive
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains? Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - News (RSS)seekingalpha·32d ago·Neutral
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm
View source ↗ - Newsseekingalpha.com·32d ago·Neutral
…line catalysts and improving growth portfolio performance. MS franchise and Alzheimer's therapies face patent expiries, competition, and limited efficacy, pressuring BIIB to deliver new blockbuster products. Growth hinges on pipeline readouts, especially litifilimab in SLE, while subQ Leqembi, Spinraza high dose, Syfovre, and Empaveli are key near-term revenue drivers.
View source ↗ - Newszacks.com·32d ago·Neutral
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsgurufocus.com·33d ago·Neutral
A Look at Biogen Inc (BIIB) After 4.1% Gain -- GF Value $202.16 vs Price $243.10 On October 20, 2026, Biogen Inc (BIIB) shares rose 4.1% to a current price of $243.10. This increase comes in the context of a 52-week range that saw lows of $1
View source ↗ - News (RSS)investing·34d ago·Neutral
Biogen to present 76-week Empaveli data at kidney conference
View source ↗ - Newsglobenewswire.com·34d ago·Positive
…PAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of Nephrology (ASN) Kidney Week taking place from October 22 to 25, 2026 in Denver, Colorado.
View source ↗ - News (RSS)thestreet·36d ago·Positive
A kidney transplant milestone has Wall Street excited about Biogen JPMorgan strongly reset its price target on the company's attractive 2027 pipeline catalysts.
View source ↗ - Newsseekingalpha.com·37d ago·Positive
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade) In 12 days, on October 28, Biogen Inc. will publish its results for the third quarter. As a reminder, in late July, the company raised its FY 2026 non-GAAP diluted EPS underlying guidance from $15.25-$16.25 to $15.85-$16.85. In Q2, Biogen's Alzheimer's collaboration revenue rose 16% YoY to $63.7 million.
View source ↗ - News (RSS)zerohedge·41d ago·Neutral
…aceMobile (ASTS) rises 4.4% after Deutsche Bank upgraded the satellite broadband operator to buy, seeing a buying opportunity in the wake of recent weakness. Biogen (BIIB) gains 4.1% as JPMorgan upgrades to overweight ahead of an increasingly compelling catalyst path in 2027. Bristol Myers (BMY) rises 4.4% after the drugmaker said a late-stage trial of a lower dose of its drug candidate for lung disease met its primary endpoint. CCC Intelligent Solutions (CCC) rises 11% as GTCR and Elliott Inves…
View source ↗ - News (RSS)investing·41d ago·Neutral
Why is Biogen stock climbing today?
View source ↗ - Newsproactiveinvestors.com·47d ago·Neutral
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share beat at $2.14, against a consensus of $2.07, when it reports on October 28, says Jefferies. Revenue should be in line at $2.6 billion, with lower cost of goods sold and research and development expenses partly offset by higher selling, general and administrative costs.
View source ↗ - Newszacks.com·47d ago·Neutral
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - News (Marketaux)gurufocus.com·51d ago·Positive
Biogen's Litifilimab Phase 2 Data Shows Progress in Lupus Treatment, BIIB Stock Nears Fair Valuation On October 02, 2026, Biogen <em[+325 characters]
View source ↗ - Newsglobenewswire.com·51d ago·Positive
…udy, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, represent the longest da…
View source ↗ - Newszacks.com·55d ago·Negative
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs? BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
View source ↗ - Newsglobenewswire.com·66d ago·Negative
…on in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology (CJASN). The dedicated subgroup analysis was first presented at the 2025 Annual Meeting of the European Soc…
View source ↗ - Newsmarketbeat.com·68d ago·Negative
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience Biogen NASDAQ: BIIB is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quarter and said its recently acquired assets could help accelerate revenue growth.
View source ↗ - News (RSS)seekingalpha·69d ago·Positive
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·71d ago·Neutral
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology Biogen NASDAQ: BIIB executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth.
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) –4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines –
View source ↗ - News (RSS)yahoo·81d ago·Neutral
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) –4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–
View source ↗ - Newsglobenewswire.com·83d ago·Negative
Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
View source ↗ - News (RSS)investing·89d ago·Neutral
Biogen commits to Veeva Vault CRM platform globally
View source ↗ - Newsglobenewswire.com·90d ago·Neutral
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.)
View source ↗ - Newsprnewswire.com·90d ago·Neutral
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 /PRNewswire/ -- Eisai Co., Ltd.
View source ↗ - Newszacks.com·94d ago·Negative
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
View source ↗
Earnings
Fri, Feb 5(in 2 months)
Consensus estimate $2.79 per share
Typical surprise +22.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 28$2.62 vs $1.99beat
- Wed, Jul 29$3.60 vs $2.94beat
- Wed, Apr 29$3.57 vs $3.05beat
- Fri, Feb 6$1.99 vs $1.63beat
- Thu, Oct 30$4.81 vs $3.88beat
- Thu, Jul 31$5.47 vs $3.90beat
Estimates and results for BIIB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BIIB officers and directors.
- Bought
- $585
- Sold
- $771k
1 trade
3 trades
- Minor Lloydsold
- Minor Lloydsold
- Murphy Nicolebought
- Singhal Priyasold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Buy$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Oct 8, 2026 (14d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 2, 2026 (15d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Jul 8, 2026 (36d later)Sell$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Jul 3, 2026 (28d later)Buy$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Jun 9, 2026 (29d later)Buy$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Jun 9, 2026 (29d later)Buy$50,001 - $100,000
- Maria Elvira Salazarhouse · FL27 · disclosed Jun 9, 2026 (28d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Feb 13, 2026 (14d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (26d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2024 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (11d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (16d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
